Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey

Europace

Volumn 17, Issue 12, 2015, Pages 1862-1867

  Potpara, Tatjana S ^a   Lenarczyk, Radoslaw ^b   Larsen, Torben B ^c   Deharo, Jean Claude ^d   Chen, Jian ^e,f   Dagres, Nikolaos ^g  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

^d TIMONE HOSPITAL   (France)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF BERGEN   (Norway)

^g UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Chronic kidney disease; EHRA survey; EP wire; Management of atrial fibrillation; Non Vitamin K oral anticoagulants; Renal replacement therapy; Stroke prevention; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIVITAMIN K; APIXABAN; CREATININE; DABIGATRAN; DRONEDARONE; EDOXABAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROPAFENONE; RIVAROXABAN; SOTALOL; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; FOLLOW UP; HEART RHYTHM; HUMAN; KIDNEY FUNCTION; PATIENT MONITORING; PATIENT PREFERENCE; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; RENAL REPLACEMENT THERAPY; ADVERSE EFFECTS; CLINICAL PRACTICE; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; EUROPE; HEALTH CARE DISPARITY; HEALTH CARE SURVEY; KIDNEY FUNCTION TEST; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; QUESTIONNAIRE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DRUG ADMINISTRATION SCHEDULE; EUROPE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEALTHCARE DISPARITIES; HUMANS; KIDNEY FUNCTION TESTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84960108642     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv416     Document Type: Article

References (9)

1. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-A position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015; 17: 1169-96.
2. Potpara TS, Lip GYH. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. Progr Cardiovasc Dis. 2015; 58: 177-94.
3. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, HackeWet al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17: 1467-507.
4. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Amer Coll Cardiol. 2014; 64: 2471-82.
5. Potpara TS, Pison L, Larsen TB, Estner H, Madrid A, Blomstrom-Lundqvist C, et al. How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe?. Results of the European Heart Rhythm Association Survey. Europace. 2015; 17: 468-72.
6. Harel Z, Sholzberg M, Shah PS, Pavenski K, Harel S, Wald R, et al. Comparisons between novel oral anticoagulants and vitamin k antagonists in patients with CKD. J Amer Soc Nephrol. 2014; 25: 431-42.
7. Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Patient outcomes using the European label for dabigatran A post-hoc analysis from the re-ly database. Thromb Haemost. 2014; 111: 933-42.
8. Hayashi M, Kaneko S, Shimano M, Ohashi T, Kubota R, Takeshita K, et al. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. Nephrol Dial Transplant. 2014; 29: 160-7.
9. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, et al. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (HRA) position document endorsed by the ESCWorking Group Thrombosis, Heart Rhythm Ssociety (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2015; 17: 1197-214.